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Invasive mould disease is a growing threat for immunocompromised patients. The optimum time to
use mould-active antifungal agents is much debated. Current approaches to antifungal prophylaxis, early
treatment (empirical and pre-emptive therapy) and treatment of documented mould infections in
onco-haematology patients are discussed.
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Introduction
Invasive mould disease (IMD) accounts for one-half to two-thirds
of all systemic mycoses in immunocompromised patients and is
most frequently caused by Aspergillus species. Over the past two
decades, the number of patients at risk has expanded due to
the wider use of intensive myelosuppressive and/or immunosup-
pressive agents in the treatment of haematological cancers, in
particular in those with acute myeloid leukaemia and myelodys-
plastic syndromes, the growing number of patients undergoing
allogeneic haematopoietic stem cell transplantation (HSCT) and
the increasing aged population.1 While the spectrum of patients
at risk is also expanding,2,3 two-thirds of these patients still
receive medical care in haematology and HSCT units. In this
setting, prolonged neutropenia and graft-versus-host disease
are the major risk factors for early and delayed occurrence of
IMD, respectively.
Epidemiological studies suggest wide variations in fungal
disease attack rates, reflecting marked differences in patient
characteristics and prevention and treatment protocols, as well
as environmental characteristics. Hence, national and even
local surveillance programmes need to be established if one
wants to tailor diagnosis and treatment more effectively to the
most prevalent fungal species. Indeed, some centres have
recently reported unusually high incidences of non-Aspergillus
mould diseases, including Fusarium spp., Scedosporium spp.
and Zygomycetes. These diseases are associated with very high
attributable mortality rates.4
Current data for invasive aspergillosis5,6 and mucormycosis7
suggest that early initiation of antifungal therapy may improve
outcome. In addition, treatment should be started with an ade-
quate drug (an adequate dose of a drug that is active against the
fungus causing the infection). The latter requires diagnostic pro-
cedures, fungal culture, species identification and possibly in vitro
susceptibility testing. Hence, to date, fungal culture, species
identification and in vitro susceptibility testing remain the corner-
stone of fungal diagnosis.
As few data are available from paediatric patients, the present
review focuses on the evidence based on studies conducted in
adult patients.
Prophylaxis
Considering the high mortality rate of IMD and the difficulties in
its diagnosis, mould-active primary prophylaxis has been advo-
cated, at least in high-risk haematology patients.8 This strategy
implies the administration of broad-spectrum antifungal
agents—usually at therapeutic doses—to all (or a significant sub-
group of) patients who are at increased risk of mould infection,
but who lack any indication of active infection at the time of
administration. Recently, new data from five large prospective
randomized clinical trials in onco-haematology patients have
been presented: (i) in an open-label multicentre study in patients
receiving chemotherapy for acute leukaemia or myelodysplastic
syndrome inducing a prolonged neutropenia, posaconazole
reduced the incidence of invasive aspergillosis to 1%, as
opposed to 7% in those receiving standard azole prophylaxis;9
(ii) in a double-blind multicentre study, posaconazole proved to
be non-inferior to fluconazole in reducing the number of invasive
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fungal infections (IFIs) in allogeneic HSCT recipients with acute or
severe chronic graft-versus-host disease, and it significantly
reduced the incidence of invasive aspergillosis while on treat-
ment;10 (iii) in a single-centre, placebo-controlled study, aeroso-
lized liposomal amphotericin B was effective in reducing the
incidence of invasive aspergillosis from 14% to 4%, and was
well tolerated;11 (iv) in a double-blind randomized study, vorico-
nazole, when compared with fluconazole in myeloablative
standard-risk allogeneic stem cell transplant recipients, tended
to reduce the incidence of invasive aspergillosis (P¼0.09), but
did not significantly improve fungus-free survival;12 (v) finally, in
a randomized open study in allogeneic HSCT recipients,
voriconazole proved to be superior to itraconazole, albeit due to
improved tolerability only.13
However, primary antifungal prophylaxis has important limit-
ations, including the potential for selection or induction of
resistant fungi, drug toxicity and drug–drug interactions, thera-
peutic drug monitoring issues and cost. Also, mould-active pro-
phylaxis may interfere with the accuracy of fungal-specific
diagnostic assays (e.g. the galactomannan assay), thereby
inducing false-negative results.14 Finally, prophylaxis is no
substitute for any of the other antifungal strategies, since
breakthrough infections do occur, including infections with
azole-resistant Candida species, Aspergillus species with inher-
ited or acquired resistance, and sometimes with species
for which we have limited (e.g. Zygomycetes) or no (e.g.
Scedosporium prolificans) remaining treatment options.15 But
most importantly, identification of the appropriate patient for
whom prophylaxis might be beneficial and delineation of the
at-risk period are not always easy, certainly not in the
absence of reliable centre-specific epidemiological data.
Indeed, the perceived benefit resulting from all these prophy-
lactic studies is largely influenced by the baseline prevalence
of mould infections in the target population.16 Lastly, while
studies on antifungal prophylaxis have focused almost exclu-
sively on patients with acute myeloid leukaemia, patients
with myelodysplastic syndromes requiring intensive chemother-
apy and recipients of allogeneic HSCT, sufficient supportive data
are lacking for patients with acute lymphocytic leukaemia and
other haematological malignancies.
Thus, the current evidence supporting mould-active prophy-
laxis should be weighed against gaps in knowledge as well as
recent improvements in the diagnosis and outcome of fungal
infections and in identifying patients who are likely to be the
best candidates for prophylaxis. In the future, antifungal pro-
phylaxis may target patients more selectively on the basis of
a specific genetic profile (see the related articles in this Sup-
plement on risk assessment and prognostic factors for
mould-related diseases in immunocompromised patients17
and the detection and investigation of IMD18).
Secondary prophylaxis or maintenance treatment, aiming
at preventing relapse of a previous IFI during a new at-risk
period, is generally recommended. The drug of choice in this
particular setting should be based on the causative fungal
pathogen and the prior response to antifungal therapy.
Recently, an open-label prospective cohort study demonstrated
the benefit of voriconazole secondary prophylaxis in allogeneic
HSCT recipients with a prior history of documented fungal
infection.19
Empirical antifungal therapy: the fever-driven
approach
This approach represents another risk-based intervention and
implies the commencement of antifungal therapy at the first
suspicion of IFI. By definition, empirical antifungal therapy
targets haematology patients that have prolonged neutropenia
(e.g. acute leukaemia/myelodysplastic syndrome or myeloabla-
tive allogeneic transplantation) with persistent or relapsing
fever despite the receipt of 4–7 days of adequate broad-
spectrum antibiotics and in the absence of other clinical symp-
toms/signs, of conventional radiological and laboratory findings
and of specific investigations aimed at documenting invasive
fungal disease (IFD) (e.g. thoracic and abdominal CT scan, detec-
tion of circulating fungal markers). This strategy was developed
in the 1980s in response to the emergence of IFIs; at that
time, the tools for diagnosing mould infections were lacking
and management was based on clinical features, blood cultures
and conventional radiology, all of which lack sensitivity.
Empirical antifungal therapy mirrors the successful empirical
antibacterial approach that was developed in the 1970s.
However, the antifungal approach has been based on moderate
evidence from clinical trials with small sample size and debatable
methodology/design. Empirical antifungal therapy considers
fungal pathogens that are not covered by the drug(s) previously
used in prophylaxis. However, the low positive predictive value of
persistent or relapsing fever for diagnosing fungal infection also
results in significant overtreatment, toxicity and expenditure.20
On the other hand, this fever-driven strategy may miss invasive
mycoses that develop in the absence of fever, especially in
patients receiving high-dose corticosteroids or other immunosup-
pressive drugs. Similar to primary prophylaxis, empirical therapy
does not completely abolish breakthrough fungal infections,
which occur in 2%–10% of cases. In addition, given the current
diagnostic possibilities, one should acknowledge that all the
empirical therapy studies have used a very limited diagnostic
work-up (i.e. often not including CT scan and new fungal blood
markers) at baseline (or later on) to confirm the presence or
absence of IMD.
Pre-emptive antifungal therapy: the
diagnostics-driven approach
Recent improvements in early diagnosis (for Aspergillus spp. in
particular) have prompted a reappraisal of the diagnostics-driven
use of antifungal agents.20–23 The time period between fungal
replication, invasion and appearance of signs and symptoms
represents a window of opportunity for earlier treatment.
However, the documentation of possible or probable fungal
infection should avoid significant and deleterious delay in the
initiation of antifungal therapy. In a way, such a diagnostics-
driven approach resembles the pre-emptive approach developed
for addressing viral infections in transplant recipients.
However, there is as yet no consensus definition of pre-
emptive antifungal therapy.23 Such therapy should not be trig-
gered by fever as a sole criterion, but should rest on: (i) a clear
identification of those patients who are at risk of fungal
disease (see the article in this Supplement on risk assessment
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and prognostic factors for mould-related diseases in immuno-
compromised patients17); and (ii) utilization of sensitive tech-
niques that facilitate rapid and early diagnosis of invasive
mould infections, e.g. galactomannan, b-D-glucan or PCR
testing as well as computerized radiological imaging techniques
(see the article on the detection and investigation of IMD in this
Supplement18). Importantly, in line with the revised European
Organization for Research and Treatment of Cancer/Mycosis
Study Group (EORTC/MSG) IFD definitions, positive mycological
test results do not define disease when considered alone—
although the predictive value may be high—but only in the pres-
ence of attributable clinical/radiological signs and symptoms,
which make diagnosis of IMD more probable.24 Therefore,
these mycological tools should be used in conjunction with
modern imaging techniques, especially since the systematic
use of pulmonary CT scan has been shown to improve earlier
diagnosis and survival in haematology patients.6
Empirical versus diagnostics-driven
approaches: the jury is still out
The excellent negative predictive value of the antigen-basedassays
whenused as screening tools on blood samplesmay persuade clin-
icians to withhold or modify antifungal therapy in neutropenic
patients with persistent or recurring fever without other clinical,
radiological and/or microbiological evidence of fungal infection.
Of note, in patients receiving mould-active prophylaxis, a reduced
positive predictive value of the galactomannan assay has been
reported, likely due to a lower pre-test probability as a result of
effective prophylaxis, reducing the incidence of IFD. Also,
mould-active prophylaxis may reduce the amount of circulating
galactomannan, resulting in a lower sensitivity of the test. Conver-
sely, in a patient population in which a positive assay correlates
with a high positive predictive value (i.e. in patients with a high
prevalence), a positive assay should trigger a diagnostic work-up,
potentially leading to early therapy.25
In haematology patients presenting with accessible pulmon-
ary nodules or lesions, we strongly recommend further investi-
gation via bronchoscopy, with lavage of the affected segment
for fungal culture, microscopy and galactomannan detection.
Indeed, positive galactomannan detection on bronchoalveolar
lavage fluid samples taken from the radiologically affected pul-
monary area supports the diagnosis of invasive pulmonary
aspergillosis. A negative test result makes the diagnosis unlikely,
although one should remember that the technique of sampling
of bronchoalveolar lavage fluid lacks standardization and that
the optimal cut-off for positivity on these samples is still a
subject of ongoing clinical research.26,27 However, a highly sug-
gestive CT scan (e.g. nodules during neutropenia) and negative
antigen-based tests should trigger a diagnostic exploration for
infection caused by one of the Zygomycetes, other rare moulds
or non-fungal pathogens.28,29
In a non-comparative pilot study, Maertens et al. prospec-
tively evaluated a therapeutic algorithm incorporating CT scan
and galactomannan detection (with an optical density cut-off
≥0.5) in 136 neutropenic episodes in adult haematology
patients.30 The study was designed to explore the feasibility of
starting antifungal therapy based on diagnostic information, in
an attempt to reduce the exposure to antifungal agents. While
a purely fever-driven approach would have resulted in antifungal
treatment in at least 41 of 136 episodes, a pre-emptive algor-
ithm led to the initiation of antifungal therapy in less than one-
quarter of these episodes, but identified 10 episodes of fungal
infection without fever or with the presence of confounding
febrile conditions. No undetected cases of invasive aspergillosis
were identified. However, one case of disseminated mucormyco-
sis was missed. The frequencies of IFI per episode and per
patient were high: 15% and 24%, respectively. The overall mor-
tality rate of 18% was acceptable for a neutropenic population
with probable IFI. Importantly, all patients received fluconazole
prophylaxis to prevent Candida infections. No patient received
mould-active prophylaxis, perhaps improving the sensitivity of
the assay and favouring the effectiveness of the pre-emptive
approach.
Recently, a non-randomized Italian study assessed the feasi-
bility of an intensive diagnostic work-up (three consecutive
galactomannan assays and chest CT scan), as opposed to
routine screening, in neutropenic patients meeting standard cri-
teria for starting empirical antifungal therapy (persistent or
recurrent fever).31 This prospective, single-centre study con-
firmed earlier findings in patients undergoing chemotherapy for
acute leukaemia and not receiving mould-active antifungal pro-
phylaxis: a diagnostics-based strategy appears to be feasible and
safe (no undiagnosed cases of fungal infection and no excess
mortality) and reduces the cost of antifungals. However, not-
withstanding these results, the authors have started to adminis-
ter mould-active prophylaxis to their acute myeloid leukaemia
population, especially given the high incidence of invasive
aspergillosis during the study period at their centre. In addition,
long-term effects of delaying antifungal therapy (e.g. impact
on subsequent anti-neoplastic therapy, including transplan-
tation) were not assessed.
In 2009, Cordonnier et al.32 presented a non-inferiority multi-
centre study comparing classical empirical and pre-emptive
treatment in 293 patients with haematological malignancies
with an expected duration of neutropenia of at least 10 days.
The primary endpoint was overall survival. Seventeen patients
developed an IFI: 4 (2.7%) in the empirical group and 13 (9%)
in the pre-emptive group (P,0.02). However, the overall survival
rates measured 2 weeks after neutrophil recovery were compar-
able (95% and 97%, respectively; P¼0.12). Subanalysis revealed
no difference between the two treatment approaches when the
duration of neutropenia was short (,15 days); however, the
longer the period of neutropenia, the greater was the risk of
fungal infection within the pre-emptive therapy arm. Also, the
non-inferiority of survival during remission–induction che-
motherapy—the subgroup with the longest duration of neutro-
penia—could not be demonstrated with certainty for the
pre-emptive group. Overall, the pre-emptive approach signifi-
cantly reduced the use of antifungal agents (39.2% versus
61.3%, P,0.001) while significantly prolonging the delay
between fever onset and initiation of antifungal therapy
(median 13 versus 7 days, P¼0.01). Again, long-term effects of
delaying antifungal therapy, other than survival, were not
assessed.
In future, prospective multicentre studies comparing pre-
emptive or empirical therapy in the era of mould-active prophy-
laxis should further determine the impact of these more tar-
geted approaches in terms of outcome and cost effectiveness.
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As recently evidenced in a clinical study evaluating PCR screen-
ing, these studies are difficult to undertake because they
require the full cooperation and compliance of all parties (clini-
cians, microbiologists, radiologists, chest physicians, nursing
team) and the strict adherence to a protocol of minimum stan-
dards of diagnosis.33 Adequate logistic support, sound communi-
cation between all parties involved, regular monitoring and
auditing of the approach, and acceptable feasibility of all
related conditions (e.g. performance of diagnostic procedures
over the weekend) are all prerequisites for a successful
diagnostics-driven approach. Such endeavours will only be poss-
ible if healthcare providers combine their efforts and establish a
consortium to support such a study using a standardized diag-
nostic approach that has gained wide acceptance. Thus far,
although many haematology centres are using a diversity of pre-
emptive approaches, no firm recommendation can be given; the
decision must be based on the local prevalence and epidemiol-
ogy of pulmonary mould infections, the availability of these
mycological tests and CT scan procedures and the routine use
of mould-active prophylaxis (Figure 1).
Targeted therapy of mould infections
Targeted antifungal therapy refers to the treatment of proven
and probable fungal infections. However, in some prospective
clinical trials, possible cases have also been included.
At present, voriconazole is recommendedworldwide as thedrug
of choice for the first-line therapy of invasive aspergillosis based on
the results of a prospective, randomized clinical trial with ampho-
tericin B deoxycholate as comparative initial therapy in possible,
probable or proven disease.34,35 This study reported significantly
better response rates and survival rates in the group of patients
that started with voriconazole (53% and 71%, respectively)
than in the control group, which started with conventional ampho-
tericin B (32% and 58%, respectively).36 Voriconazole is also con-
sidered the drug of choice for the treatment of cerebral
aspergillosis.37 However, particular clinical conditions favour the
use of a non-azole-based primary treatment; these conditions
include prior exposure to mould-active azoles, the concomitant
use of contraindicated medication (e.g. sirolimus), the risk of
severe drug interactions, moderate to severe hepatic or renal
impairment (the intravenous formulation of voriconazole is
discouraged in patients with a creatinine clearance of ,50 mL/
min) and the presence of mixed fungal infections (e.g. including
Zygomycetes). In addition, multiazole-resistant species of
Aspergillus fumigatus have been described and appear to be
emerging.38
More recently, theAmBiLoad trial compared twodoses of liposo-
mal amphotericin B: a standard dose of 3 mg/kg/day versus a
loading dose (for the first 14 days only) of 10 mg/kg/day. The
study failed to show any advantage for the higher dose, which
also proved to be more toxic and was associated with a trend
towards a higher mortality rate.39 Similar to the pivotal trial of vor-
iconazole, the study was debated because almost 60% of the
patients in the study population were enrolled based on the pres-
ence of suggestive radiological features only,without anymicrobio-
logical confirmation, i.e. possible disease.40 Thus, although the
3 mg/kg study arm reported efficacy results and survival data
similar to the aforementioned voriconazole study, because of the
lack of a direct comparison, liposomal amphotericin B is considered
the alternative drug of choice for the first-line therapy of invasive
aspergillosis. Of note, Aspergillus terreus infections display evidence
of decreased activity of amphotericin B in vitro and in vivo and
should be treated with a mould-active azole.41
Population at
risk for IFD
No
prophylaxis
Empirical Diagnostics-driven
Fluconazole
prophylaxis
Empirical Diagnostics-driven
Mould-active
prophylaxis
Empirical Diagnostics-driven
Empirical
No diagnostic
facilities available
Use only to buy time
until IFD is confirmed
or excluded
Diagnostics-driven
Screening tests
implemented
Results same/next day
CT-scan accessible
Bronchoscopy available
Diagnostics-driven
Screening tests
unreliable
CT-scan accessible
Bronchoscopy
available
Preventative strategy
Figure 1. Antifungal strategies for patients at risk of invasive fungal disease (IFD).
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Data regarding the use of echinocandins in the primary
therapy of invasive aspergillosis are scarce. The activity of caspo-
fungin has recently been assessed in a non-comparative Phase II
study in two different cohorts: patients with haematological dis-
orders (n¼61)42 and patients undergoing allogeneic HSCT
(n¼24).43 Overall, the rates of favourable responses were 33%
and 42%, respectively. However, a fair comparison with pre-
viously published data is not possible since all patients had
mycologically documented disease and the majority had poor
baseline characteristics, such as uncontrolled underlying
disease, older age and low performance score. The enormous
impact of baseline characteristics on outcome has also been
observed by other investigators; recovery from neutropenia in
particular was a major determinant of response. Nevertheless,
given these results, caspofungin cannot be recommended as
first-line therapy for invasive aspergillosis, but it provides an
option for patients not able to receive or tolerate voriconazole
or liposomal amphotericin B.
It remains difficult to estimate the number of patients who are
refractory to first-line therapy since an accurate assessment of the
response to primary therapy is particularly difficult. The assess-
ment uses conventionally defined global response composite end-
points that rely on non-specific signs and symptoms of infection,
subjective interpretation of attributable radiological findings, and
repeated culture and histopathological testing, both of which are
rarely available.44,45 In addition, often the cause of death cannot
be unequivocally documented. Moreover, transient deterioration
due to immune reconstitution inflammatory syndrome as a
result of neutrophil recovery or tapering of immunosuppression
may further obscure outcomeassessment.46 Thus, there is a press-
ing need for a specific and quantifiable surrogate marker for
outcome evaluation. Miceli et al.47 postulated that the serum
galactomannan test fulfils the requirements of surrogacy for
outcome evaluation in aspergillosis, and they summarized the evi-
dence favouring serum galactomannan over conventional
outcome markers. They demonstrated a strong correlation
between unambiguous clinical outcome endpoints (such as survi-
val) and the evolution of serum galactomannan. Whether serum
galactomannan, or perhaps b-D-glucan, is a reliable surrogate
marker of response remains to be further investigated.
As mentioned, treatment should be started with an adequate
dose of the drug of choice. However, recent observations have
ascribed severe drug-related toxicities, as well as therapeutic
failure of mould-active azoles, to unexpectedly high or low
serum concentrations due to interpatient and intrapatient varia-
bility in exposure, underscoring the potential need for therapeutic
drug monitoring (see the article in this Supplement on the detec-
tion and investigation of invasive mould disease).18 Overall, up to
50% of the patients who fail first-line therapy (as per conventional
criteria) can be salvaged with second-line use of caspofungin,
posaconazole or a lipid formulation of amphotericin B. Whereas
the availability of new agents with different modes of action
and promising preclinical studies has fuelled interest in the clinical
use of combination antifungal therapy (in particular the combi-
nation of an echinocandin with a mould-active azole or a
formulation of amphotericin B), this approach has only been
evaluated in studies with insufficient statistical power. A large,
randomized clinical trial in haematology patients is currently
ongoing and will provide more insights on the general usefulness
of drug combinations in first line therapy.
Recent guidelines recommend the combined use of antifun-
gal therapy with surgical debridement, particularly in the CNS
and sinus invasive mould infections, and for the prevention of
severe haemorrhage when pulmonary lesions are adjacent to a
large vessel.34,35 In addition, several in vitro and in vivo data
underscore the importance of restoration of the host immune
defence (i.e. granulocyte transfusions, as well as the use of hae-
matopoietic growth factors or cytokines and the preservation of
organ function) for the outcome of fungal disease.
Voriconazole and lipid formulations of amphotericin B are the
drugs of choice for the treatment of invasive infection caused by
Fusarium48 and Scedosporium spp.49 Systemic antifungal treat-
ment should, whenever possible, be combined with surgical
debridement of necrotic tissue. Posaconazole can be used as
salvage therapy for these infections.
Finally, a lipid-based formulation of amphotericin B is the drug
of choice for the first-line therapy of invasive mucormycosis;50
some authors have recommended higher than usual doses:
5–10 mg/kg/day for liposomal amphotericin B and 5–7.5 mg/
kg/day for amphotericin B lipid complex. Posaconazole may be
used for salvage or maintenance treatment. Antifungal therapy
should be complemented by surgical debridement and reversal
of underlying predisposing factors (such as diabetic ketoacidosis,
iron overload, steroid treatment or neutropenia).
There is no firm recommendation about the duration of anti-
fungal therapy in the treatment of invasive mould infections.
Although a minimum duration of 6–12 weeks has been
suggested for invasive aspergillosis in particular, we feel that
the duration should be dictated by the severity and duration of
the underlying immune deficits and the complete reversal of
all relevant signs and symptoms of the infection.
Conclusions
IMD is mainly caused by Aspergillus spp. The clinical manage-
ment is hampered by the difficulty of diagnosing these infections
since definite diagnosis centres on histological identification of
hyphae in tissue or on culture from a sterile body site. In high-risk
populations, most practitioners therefore rely on antifungal
prophylaxis. Recently, there has been a shift in emphasis
from routine prophylaxis to screening high-risk patients so that
appropriate antifungal therapy can be administered early,
when it can potentially improve patient outcome. Although
they do not provide fungal species identification and antifungal
susceptibility results, non-culture based mycological tools are
one of the key elements of this change in practice. Together
with assessment of clinical signs, cultures and CT scanning,
they may prove useful for starting antifungal therapy pre-
emptively. In the light of changing fungal epidemiology in
some (but not all) centres, future studies should focus on the
combined use of ‘panfungal’ (PCR and b-D-glucan) and ‘species-
specific’ (e.g. galactomannan) assays, in conjunction with
sensitive imaging studies.
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